This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
“Cholesterol does not cause heart disease.“ “Statins do not prevent heart attacks.” These are two statements you will hear repeatedly on social media. Usually made by those who really don’t understand what they are saying but increasingly by doctors who really should know better. In the middle of this hurricane of noise are people who just want to know what to do so they don’t have a heart attack at a young age.
Greetings! Welcome to the Physiology Friday newsletter. If you’re looking for a new (mess-free) way to fuel your workouts, you should check out Intra Chew—it’s a workout gummy bear made by one of my friends that has carbohydrates and electrolytes. I’ve been using them during all of my long bike rides and before runs. At the very least, it’s something you should try once, and you can get 20% off using the code BRADY20 on the site.
Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart attack and stroke among these patients, according to results from an international clinical trial led by a Mount Sinai researcher.
tim.hodson Fri, 02/14/2025 - 14:32 Feb. 12, 2025 Orchestra BioMed Holdings, a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, recently made anoral presentation of data on the benefits of atrioventricular interval modulation (AVIM) therapy on patients with diastolic dysfunction at the Technology and Heart Failure Therapeutics (THT) 2025 Conference in Boston, Mass.
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Lorraine and Bill Dodero tim.hodson Fri, 02/14/2025 - 15:33 Feb. 10, 2025 A generous gift of $5 million from Lorraine and Bill Dodero will establish the Lorraine and Bill Dodero Limb Preservation Center at University Hospitals Harrington Heart & Vascular Institute in Cleveland, Ohio. Led by Mehdi Shishehbor DO, MPH, PhD, interventional cardiologist and a pioneer in the field of limb preservation, the Dodero Center will revolutionize care for patients at risk of losing a leg due to peripheral ar
Researchers at the University of Toronto's Institute of Biomedical Engineering have found that studying blood flow in leg muscles may help detect cardiovascular disease earlier than standardized tests, opening the door to earlier treatment and better outcomes.
Researchers at the University of Toronto's Institute of Biomedical Engineering have found that studying blood flow in leg muscles may help detect cardiovascular disease earlier than standardized tests, opening the door to earlier treatment and better outcomes.
(MedPage Today) -- The FDA approved insulin-aspart-szjj (Merilog) as the first rapid-acting insulin biosimilar product to treat adults and children with diabetes, the agency announced Friday. Like its reference counterpart, insulin aspart (Novolog.
(MedPage Today) -- The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk patients with type 2 diabetes (T2D), chronic kidney disease (CKD), and cardiovascular risk factors, a prespecified.
People living with diabetes mellitus (DM) and chronic kidney disease (CKD) are at significantly high risk of cardiovascular events (CVEs), however the predictive performance of traditional risk prediction meth.
Mr. M. was notorious, and hed managed to antagonize nearly everyone who cared for him each time he appeared at the hospital. How was a clinician supposed to find the requisite empathy in cases like his?
Nearly 80% of patients with lung cancer had detectable atherosclerosis on their cancer staging CT scans and other cardiovascular risk factors were common, offering an opportunity for earlier cardiac testing and risk factor modification, according to a new study.
The stress hyperglycemia ratio (SHR) was developed to reduce the effects of long-term chronic glycemic factors on stress hyperglycemia levels, which was associated with adverse clinical outcomes. This study ai.
These data highlight deucravacitinibs impact among patients with psoriasis who are biologic- and apremilast-naive and those with prior histories with these treatments.
Discover the incredible success and growth of Northwestern Health's Bluhm Cardiovascular Institute, ranked among the top 10 cardiology programs in the nation
Lorraine and Bill Dodero tim.hodson Fri, 02/14/2025 - 15:33 Feb. 10, 2025 A generous gift of $5 million from Lorraine and Bill Dodero will establish the Lorraine and Bill Dodero Limb Preservation Center at University Hospitals Harrington Heart & Vascular Institute in Cleveland, Ohio. Led by Mehdi Shishehbor DO, MPH, PhD, interventional cardiologist and a pioneer in the field of limb preservation, the Dodero Center will revolutionize care for patients at risk of losing a leg due to peripheral ar
Purpose Our study aims to evaluate the outcomes of children with congenital lung malformation (CLM) who have undergone surgical resection. Methods A retrospective analysis was conducted among children under 18 who were diagnosed with CLM and underwent surgery at Srinagarind Hospital, Khon Kaen University between January 2007 and December 2023. We collected data on surgical outcomes, including operative time, postoperative complications, and mortality rate.
Unnecessary blood preparation by surgeons adversely affects blood bank stocks and the healthcare system in many ways. In this study, it is aimed to evaluate the patient blood management strategy in patients in.
The Systemic Immune-Inflammation Index (SII) is a novel biomarker of systemic inflammation. We explored the association between the SII and metabolic syndrome (MetS) and its components in middle-aged and older.
Chest trauma may precipitate a spectrum of injuries, among which tracheal laceration represents an uncommon but critical sequela. The occurrence of tracheal laceration could significantly impair respiratory an.
Blood thinners prescribed after blood clots in the leg or lung initially increase the risk of bleeding, especially in women and the elderly. But over time, this risk decreases and gender and age differences fade, a University of Gothenburg study shows.
Studies show conflicting results regarding the impact of the COVID-19 pandemic on the treatment of patients with coronary artery disease requiring cardiac surgery and data from Germany are lacking. In this stu.
Several cardiovascular risk factors, such as advanced age and smoking history, are prevalent among lung cancer patients at the time of the diagnosis and increase their risk of future heart disease, according to a new study being presented at ACC's Advancing the Cardiovascular Care of the Oncology Patient course. Comprehensive assessments are needed in this vulnerable group to improve survival outcomes and quality of care for cancer patients.
(MedPage Today) -- For some patients with atrial fibrillation (Afib, AF) and valvular heart disease (VHD), direct oral anticoagulants (DOACs) appeared to offer better prevention of stroke and thromboembolic events compared with warfarin, without.
Journal of the American Heart Association, Ahead of Print. BackgroundDespite proven efficacy and safety of direct oral anticoagulants (DOACs) over warfarin in patients with atrial fibrillation (AF), data on patients with AF and valvular heart disease remain scarce. We aimed to evaluate the DOACs compared with warfarin among patients with AF and valvular heart disease.Methods and ResultsWe conducted a retrospective cohort study of patients 18 years of age, who had AF and valvular heart disease, a
Panelists discuss how the ENHANCE trials assessed ensifentrine in patients with chronic obstructive pulmonary disease (COPD) with moderate-to-severe airflow obstruction and a history of exacerbations. Outcomes showed improved lung function and reduced exacerbations. Clinically, ensifentrine may be used as monotherapy or an add-on, addressing diverse patient needs.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
112 
Let's personalize your content